Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, SC, USA.
Department of Biomedical Engineering, University of South Carolina School of Medicine, Columbia, SC, USA.
Biochim Biophys Acta Gen Subj. 2018 May;1862(5):1069-1078. doi: 10.1016/j.bbagen.2018.01.020. Epub 2018 Feb 2.
Interleukin-6 is a gp130 utilizing cytokine that is consistently associated with allergic diseases like asthma and urticaria in humans where mast cells are known to play a critical role. However, the role of IL-6 in allergic disease in not known. IL-6 was reported to enhance degranulation of in vitro-derived mast cells, but the effect of IL-6 on mediator release from human in situ-matured tissue-isolated mast cells had not been reported.
Human mature mast cells were isolated and purified from normal skin tissue from different donors. The expression of surface-expressed IL-6 receptors was demonstrated by flow cytometry. The effect of IL-6 on FcεRI-induced degranulation, PGD biosynthesis, and cytokine production was determined with β‑hexosaminidase release assay, Western blotting, quantitative real-time PCR, and ELISA. The small molecule inhibitor of STAT-3, C188-9, was used to demonstrate STAT3 dependency.
IL-6 significantly potentiated FcεRI-induced PGD biosynthesis, but had no effect on degranulation. IL-6 also induced VEGF gene expression and protein secretion, and enhanced FcεRI-induced IL-8 production. Mechanistically, IL-6 enhanced FcεRI-induced COX‑2 expression, PGD2 biosynthesis, and VEGF production in a STAT3 dependent manner.
Here, we demonstrate that IL-6 is a potentiator of FcεRI-induced PGD biosynthesis, and can induce or enhance production of pro-angiogenesis factors VEGF and IL-8 from human in situ-matured skin mast cells.
These findings from this study indicate that IL-6 contributes to human allergic disease by enhancing the production of inflammatory PGD from tissue-resident mast cells. Moreover, the data suggest a novel role for IL-6 in mast cell-mediated angiogenesis.
白细胞介素-6 是一种 gp130 利用细胞因子,与哮喘和荨麻疹等过敏性疾病在人类中始终相关,其中肥大细胞被认为起着关键作用。然而,IL-6 在过敏性疾病中的作用尚不清楚。据报道,IL-6 增强了体外衍生的肥大细胞的脱颗粒作用,但尚未报道 IL-6 对人原位成熟组织分离的肥大细胞介质释放的影响。
从不同供体的正常皮肤组织中分离和纯化人成熟肥大细胞。通过流式细胞术证明表面表达的 IL-6 受体的表达。用β-己糖胺酶释放测定、Western 印迹、实时定量 PCR 和 ELISA 测定 IL-6 对 FcεRI 诱导的脱颗粒、PGD 生物合成和细胞因子产生的影响。使用 STAT3 的小分子抑制剂 C188-9 来证明 STAT3 依赖性。
IL-6 显著增强了 FcεRI 诱导的 PGD 生物合成,但对脱颗粒没有影响。IL-6 还诱导了 VEGF 基因表达和蛋白分泌,并增强了 FcεRI 诱导的 IL-8 产生。从机制上讲,IL-6 以 STAT3 依赖的方式增强了 FcεRI 诱导的 COX-2 表达、PGD2 生物合成和 VEGF 产生。
在这里,我们证明 IL-6 是 FcεRI 诱导的 PGD 生物合成的增强剂,并且可以诱导或增强来自人原位成熟皮肤肥大细胞的促血管生成因子 VEGF 和 IL-8 的产生。
本研究的结果表明,IL-6 通过增强组织驻留肥大细胞中炎性 PGD 的产生,促进人类过敏性疾病的发生。此外,数据表明 IL-6 在肥大细胞介导的血管生成中具有新的作用。